市场调查报告书
商品编码
1541023
2024-2032 年按治疗类型(连续性门诊腹膜透析、自动腹膜透析)、产品、最终用户和地区分類的腹膜透析市场报告Peritoneal Dialysis Market Report by Treatment Type (Continuous Ambulatory Peritoneal Dialysis, Automated Peritoneal Dialysis ), Product, End User, and Region 2024-2032 |
IMARC Group年全球腹膜透析市场规模达173亿美元。
腹膜透析(PD)代表一种肾衰竭治疗程序,其中透过手术将软塑胶管或导管放置在腹壁或腹部。一旦定位,无菌清洁液就会透过管道传输,透过清除废物来帮助过滤人体内的血液。一段时间后,液体和过滤后的不需要的成分从腹部流出并被丢弃。 PD分为连续性非卧床腹膜透析和连续循环腹膜透析(CCPD)。这些方法提供了治疗灵活性,减少了前往透析中心的需要,并提供了更好的临床结果,从而减少了药物和食物限制。除此之外,它可以在家中进行,而且是无针的;因此,医院和医疗中心使用 PD 来治疗肾衰竭。
高血压、糖尿病和末期肾病(ESRD)盛行率的不断上升,肾臟捐赠者的日益短缺,以及消费者对肾臟移植相关风险的认识不断增强,这些都是市场成长的主要动力。此外,对居家透析治疗的需求不断增长,特别是在 COVID-19 大流行期间,是另一个成长诱导因素。此外,各种技术的出现,例如自动腹膜透析(APD),为患者进行肾臟替代治疗和夜间多次交换,都有助于市场成长。这类先进产品有助于降低腹膜炎和疝气的发生率,并提供更好的小溶质清除率,特别是对于面临慢性肾臟病 (CKD) 的老年人群。此外,医疗从业者对帕金森氏症的倾向超过了血液透析,因为它可以确保以具有成本效益的价格提高患者流动性,同时减少症状波动,这正在推动市场成长。除此之外,政府对研发活动(R&D)的广泛投资、改善报销政策以及持续的产品多样化正在积极刺激市场成长。
The global peritoneal dialysis market size reached US$ 17.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.38% during 2024-2032.
Peritoneal dialysis (PD) represents a type of kidney failure treatment procedure wherein a soft plastic tube or catheter is placed in the abdominal lining or belly through surgery. Once it is positioned, a sterile cleansing fluid is transmitted by the duct that helps filter the blood inside an individual's body by removing waste products. After a period of time, the liquid and filtered unwanted components flow out of the abdomen and are discarded. PD is differentiated into continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis (CCPD). These approaches offer treatment flexibility, reduce the need to visit dialysis centers, and provide better clinical outcomes, resulting in lesser medications and fewer food restrictions. Apart from this, it can be carried out at home and is needle-free; thus, PD is used by hospitals and healthcare centers to treat kidney failures.
The increasing prevalence of hypertension, diabetes, and end-stage renal disease (ESRD), the rising shortages of kidney donors, and the emerging awareness amongst consumers regarding the risks associated with kidney transplants are majorly driving the market growth. Moreover, the growing need for home dialysis treatments, especially during the COVID-19 pandemic, is acting as another growth-inducing factor. Furthermore, the advent of various technologies, such as automated peritoneal dialysis (APD), to perform renal replacement therapy for patients and multiple exchanges at night is contributing to the market growth. Such advanced products aid in lowering the incidences of peritonitis and hernias and offer better small solute clearances, especially to the geriatric population facing chronic kidney disease (CKD). Additionally, the shifting inclination of health practitioners toward PD over haemodialysis as it ensures greater patient mobility at cost-effective prices while creating fewer symptom fluctuations is propelling the market growth. Apart from this, extensive investments in research and development activities (R&D) by governments, improving reimbursement policies, and the ongoing product diversification are positively stimulating the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global peritoneal dialysis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type, product and end user.
Continuous Ambulatory Peritoneal Dialysis (CAPD)
Automated Peritoneal Dialysis (APD)
Peritoneal Dialysis Solution
Peritoneal Dialysis Devices
Peritoneal Dialysis Sets
Peritoneal Dialysis Catheters
Others
Home-based Dialysis
Dialysis Centers and Hospital-based Dialysis
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amecath, Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, Medical Components Inc., Medionics International Inc., Medtronic plc, Merit Medical Systems Inc., Mitra Industries Pvt. Ltd., Newsol Technologies Inc., Nipro Canada (Nipro Medical Corporation), Poly Medicure Limited, Terumo Corporation and Utah Medical Products Inc.